Daratumumab in AL amyloidosis

2.

Kastritis

E

,

Palladini

G

,

Minnema

MC

, et al;

ANDROMEDA Trial Investigators

.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

.

N Engl J Med

.

2021

;

385

(

1

):

46

-

58

.

3.

Comenzo

RL

,

Vosburgh

E

,

Simms

RW

, et al.

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients

.

Blood

.

1996

;

88

(

7

):

2801

-

2806

.

4.

Cibeira

MT

,

Sanchorawala

V

,

Seldin

DC

, et al.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

.

Blood

.

2011

;

118

(

16

):

4346

-

4352

.

5.

Kyle

RA

,

Gertz

MA

,

Greipp

PR

, et al.

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

.

N Engl J Med

.

1997

;

336

(

17

):

1202

-

1207

.

6.

Palladini

G

,

Russo

P

,

Nuvolone

M

, et al.

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

.

Blood

.

2007

;

110

(

2

):

787

-

788

.

7.

Wechalekar

AD

,

Goodman

HJ

,

Lachmann

HJ

,

Offer

M

,

Hawkins

PN

,

Gillmore

JD

.

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

.

Blood

.

2007

;

109

(

2

):

457

-

464

.

8.

Oliva

L

,

Orfanelli

U

,

Resnati

M

, et al.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity

.

Blood

.

2017

;

129

(

15

):

2132

-

2142

.

9.

Reece

DE

,

Hegenbart

U

,

Sanchorawala

V

, et al.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

.

Blood

.

2014

;

124

(

16

):

2498

-

2506

.

10.

Venner

CP

,

Lane

T

,

Foard

D

, et al.

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

.

Blood

.

2012

;

119

(

19

):

4387

-

4390

.

11.

Mikhael

JR

,

Schuster

SR

,

Jimenez-Zepeda

VH

, et al.

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

.

Blood

.

2012

;

119

(

19

):

4391

-

4394

.

12.

Manwani

R

,

Cohen

O

,

Sharpley

F

, et al.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

.

Blood

.

2019

;

134

(

25

):

2271

-

2280

.

13.

Palladini

G

,

Sachchithanantham

S

,

Milani

P

, et al.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

.

Blood

.

2015

;

126

(

5

):

612

-

615

.

14.

Muchtar

E

,

Gertz

MA

,

Kumar

SK

, et al.

Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

.

Blood

.

2017

;

129

(

15

):

2111

-

2119

.

15.

Ravichandran

S

,

Lachmann

HJ

,

Wechalekar

AD

.

Epidemiologic and Survival Trends in Amyloidosis, 1987-2019

.

N Engl J Med

.

2020

;

382

(

16

):

1567

-

1568

.

16.

Staron

A

,

Zheng

L

,

Doros

G

, et al.

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

.

Blood Cancer J

.

2021

;

11

(

8

):

139

.

17.

Dubrey

SW

,

Reece

DE

,

Sanchorawala

V

, et al;

Velcade Can2007 Study Group

.

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

.

QJM

.

2011

;

104

(

11

):

957

-

970

.

18.

Venner

CP

,

Gillmore

JD

,

Sachchithanantham

S

, et al.

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

.

Leukemia

.

2014

;

28

(

12

):

2304

-

2310

.

19.

Muchtar

E

,

Gertz

MA

,

Lacy

MQ

, et al.

Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio

.

Am J Hematol

.

2020

;

95

(

11

):

1280

-

1287

.

20.

Sarosiek

S

,

Varga

C

,

Jacob

A

,

Fulciniti

MT

,

Munshi

N

,

Sanchorawala

V

.

Detection of minimal residual disease by next generation sequencing in AL amyloidosis

.

Blood Cancer J

.

2021

;

11

(

6

):

117

.

21.

Palladini

G

,

Paiva

B

,

Wechalekar

A

, et al.

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

.

Blood Cancer J

.

2021

;

11

(

2

):

34

.

22.

Staron

A

,

Burks

EJ

,

Lee

JC

,

Sarosiek

S

,

Sloan

JM

,

Sanchorawala

V

.

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis

.

Blood Adv

.

2020

;

4

(

5

):

880

-

884

.

23.

Ravichandran

S

,

Cohen

OC

,

Law

S

, et al.

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib

.

Blood Cancer J

.

2021

;

11

(

6

):

118

.

24.

Sher

T

,

Fenton

B

,

Akhtar

A

,

Gertz

MA

.

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis

.

Blood

.

2016

;

128

(

15

):

1987

-

1989

.

25.

Kaufman

GP

,

Schrier

SL

,

Lafayette

RA

,

Arai

S

,

Witteles

RM

,

Liedtke

M

.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis

.

Blood

.

2017

;

130

(

7

):

900

-

902

.

26.

Abeykoon

JP

,

Zanwar

S

,

Dispenzieri

A

, et al.

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

.

Leukemia

.

2019

;

33

(

2

):

531

-

536

.

27.

Lee

H

,

Tay

J

,

Duggan

P

, et al.

The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience

.

Eur J Haematol

.

2021

;

106

(

3

):

340

-

345

.

28.

Chung

A

,

Kaufman

GP

,

Sidana

S

, et al.

Organ responses with daratumumab therapy in previously treated AL amyloidosis

.

Blood Adv

.

2020

;

4

(

3

):

458

-

466

.

29.

Van de Wyngaert

Z

,

Carpentier

B

,

Pascal

L

, et al.

Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population

.

Br J Haematol

.

2020

;

188

(

3

):

e24

-

e27

.

30.

Milani

P

,

Basset

M

,

Curci

P

, et al.

Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function

.

Blood Adv

.

2020

;

4

(

7

):

1321

-

1324

.

31.

Kimmich

CR

,

Terzer

T

,

Benner

A

, et al.

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

.

Blood

.

2020

;

135

(

18

):

1517

-

1530

.

32.

Lecumberri

R

,

Krsnik

I

,

Askari

E

, et al.

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

.

Amyloid

.

2020

;

27

(

3

):

163

-

167

.

33.

Sanchorawala

V

,

Sarosiek

S

,

Schulman

A

, et al.

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

.

Blood

.

2020

;

135

(

18

):

1541

-

1547

.

34.

Szalat

RE

,

Gustine

J

,

Sloan

JM

,

Edwards

CV

,

Sanchorawala

V

.

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

.

Am J Hematol

.

2022

;

97

(

1

):

79

-

89

.

35.

Cohen

OC

,

Brodermann

MH

,

Blakeney

IJ

, et al.

Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis

.

Amyloid

.

2020

;

27

(

3

):

200

-

205

.

36.

Shragai

T

,

Gatt

M

,

Lavie

N

, et al.

Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review

.

Eur J Haematol

.

2021

;

106

(

2

):

184

-

195

.

37.

Roussel

M

,

Merlini

G

,

Chevret

S

, et al.

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

.

Blood

.

2020

;

135

(

18

):

1531

-

1540

.

38.

Luo

MM

,

Zhu

PP

,

Nnane

I

, et al.

Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis

.

J Clin Pharmacol

.

2022

;

62

(

5

):

656

-

669

.

39.

Comenzo

R

,

Palladini

G

,

Kastritis

E

, et al.

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

.

Blood

.

2021

;

138

(

suppl 1

).

40.

Muchtar

E

,

Gertz

MA

,

Kourelis

TV

, et al.

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

.

Leukemia

.

2020

;

34

(

4

):

1135

-

1143

.

41.

Bochtler

T

,

Hegenbart

U

,

Kunz

C

, et al.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens

.

J Clin Oncol

.

2015

;

33

(

12

):

1371

-

1378

.

42.

Premkumar

VJ

,

Lentzsch

S

,

Pan

S

, et al.

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

.

Blood Cancer J

.

2021

;

11

(

1

):

10

.

43.

Cuenca

I

,

Alameda

D

,

Sanchez-Vega

B

, et al.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

.

Leukemia

.

2021

;

35

(

1

):

245

-

249

.

44.

Edwards

CV

,

Rao

N

,

Bhutani

D

, et al.

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

.

Blood

.

2021

;

138

(

25

):

2632

-

2641

.

45.

Wall

JS

,

Martin

EB

,

Endsley

A

, et al.

First in Human Evaluation and Dosimetry Calculations for Peptide ¹²⁴I-p5 + 14-a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging

.

Mol Imaging Biol

.

2022

;

24

(

3

):

479

-

488

.

46.

Manwani

R

,

Page

J

,

Lane

T

, et al.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement

.

Amyloid

.

2018

;

25

(

4

):

247

-

252

.